Diet Pill Rimonabant Seen Emerging as the Top Diet Drug in 2010
Even though diet pill rimonabant (Acomplia / Zimulti) remains stalled at the FDA, and in the next few years may face stiff competition from several drugs already in or moving into phase III trials, a leading research firm forecasts that Acomplia will be the clinical gold standard for treating obesity in 2010.
Decision Resources, Inc., in a new report issued March 19th, predicted that rimonabant's side effects of anxiety and depression in some patients "will not stop Acomplia's rise to the top," with it replacing prescription drug Xenical (orlistat) as the top selling diet drug.
» Leave a comment
- Your E-mail address is never displayed. If you enter it, it will only be visible to the blog author
- The line and paragraph breaks automatically